Prosecution Insights
Prosecution Insights
Tech Center 4100 • Art Units: 1623 1625 1626 1629 1699 4121
This examiner grants 65% of resolved cases
Alicia L. Otton works in Art Unit 1623 of Tech Center 4100 and has a volume of 1276 resolved cases. Her allowance rate stands at 65.0 percent, which provides a baseline for understanding her approach to patent examination. This 65.0 percent rate indicates a standard of review across a number of applications. The 1276 resolved cases provide a data set for understanding her approach to patent examination in Art Unit 1623.
The median days to allowance for this examiner is 959, which is a metric for planning prosecution timelines. While the 65.0 percent allowance rate is stable, the interview lift of 9.3 percent suggests a positive benefit from conducting interviews. This 9.3 percent lift indicates that verbal advocacy can help clarify technical points and potentially speed up the 959-day process. Applicants should consider these figures when deciding whether to pursue an interview or rely on written responses. The data from 1276 resolved cases suggests that Art Unit 1623 offers a predictable path to patent issuance.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18038511 | ORGANIC LIGHT EMITTING DEVICE | Non-Final OA | LG CHEM, LTD. |
| 18426920 | SYNTHESIS OF NOVEL CEREBLON E3 LIGASE LIGANDS, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Non-Final OA | Wisconsin Alumni Research Foundation |
| 18688195 | CONTROLLED LONG-TERM DRUG DELIVERY AND METHODS THEREOF | Final Rejection | THE JOHNS HOPKINS UNIVERSITY |
| 18250404 | METHODS FOR TREATING HEMATOLOGIC MALIGNANCIES WITH AMINO-PYRROLOPYRIMIDINONE COMPOUNDS | Final Rejection | Merck Sharp & Dohme LLC |
| 17998909 | COMPOUNDS FOR THE TREATMENT OF SARS | Final Rejection | Purdue Research Foundation |
| 18705065 | PYRAZOLOPYRIMIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | Non-Final OA | Japan Tobacco Inc. |
| 18041241 | QUORUM SENSING INHIBITORS AND METHODS OF USE | Non-Final OA | The Trustees of Indiana University |
| 17826660 | SULFUR (VI) FLUORIDE COMPOUNDS AND METHODS FOR THE PREPARATION THEREOF | Final Rejection | THE SCRIPPS RESEARCH INSTITUTE |
| 18785078 | PROCESS FOR THE MANUFACTURE OF A HER2 INHIBITOR | Non-Final OA | Boehringer Ingelheim International GmbH |
| 18865278 | NEW INDAZOLE DERIVATIVES | Non-Final OA | Hoffmann-La Roche Inc. |
| 18875513 | TRIAZINANE COMPOUND AND COMPOSITION CONTAINING SAME | Non-Final OA | SUMITOMO CHEMICAL COMPANY, LIMITED |
| 18729910 | TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Non-Final OA | CENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE, CHINESE ACADEMY OF SCIENCES |
| 18221140 | MITOCHONDRIA-TARGETING PEPTIDES | Non-Final OA | Stealth BioTherapeutics Inc. |
| 18687111 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND USE THEREOF | Final Rejection | IMPACT THERAPEUTICS (SHANGHAI), INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy